期刊文献+

miRNA-31生物学功能及其与肿瘤关系的研究进展 被引量:1

下载PDF
导出
摘要 微小RNA(miRNA)是一类长20~25个核苷酸的单链RNA分子,能调节靶基因的表达及相关信号通路,发挥抑癌基因或原癌基因的功能,从而影响肿瘤的发生发展。miRNA-31在多种肿瘤中异常表达,在不同类型的肿瘤中发挥不同甚至完全相反的作用,其异常表达与肿瘤的发生发展密切相关。此外,miRNA可能成为肿瘤早期诊断的标志物,对肿瘤的诊断和预后具有潜在的应用价值。目前一些研究提供了与miRNA-31失调相关的上游和下游事件的信息,有助于揭示恶性肿瘤发生的分子机制。本文对miRNA-31在恶性肿瘤发生发展、转移及治疗等方面的研究进展进行综述。
出处 《癌症进展》 2021年第18期1837-1841,共5页 Oncology Progress
基金 宁波市自然基金项目(2017A610251) 国家级大学生创新创业计划(201911646021) 浙江省大学生科技创新活动计划(2019R405009)。
  • 相关文献

参考文献2

二级参考文献59

  • 1Xiang L, Zhan Q, Zhao XH, Wang YD, An SL, Xu YZ, Li AM,Gong W, Bai Y, Zhi FC, Liu SD. Risk factors associated withmissed colorectal flat adenoma: a multicenter retrospective tandemcolonoscopy study. World J Gastroenterol 2014; 20: 10927-10937#[PMID: 25152596 DOI: 10.3748/wjg.v20.i31.10927].
  • 2Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H.Comparison of 17,641 patients with right- and left-sided coloncancer: differences in epidemiology, perioperative course, histology,and survival. Dis Colon Rectum 2010; 53: 57-64 [PMID: 20010352DOI: 10.1007/DCR.0b013e3181c703a4].
  • 3Moritani K, Hasegawa H, Okabayashi K, Ishii Y, Endo T, KitagawaY. Difference in the recurrence rate between right- and left-sidedcolon cancer: a 17-year experience at a single institution. SurgToday 2014; 44: 1685-1691 [PMID: 24126535 DOI: 10.1007/s00595-013-0748-5].
  • 4Wiggers T, Arends JW, Volovics A. Regression analysis ofprognostic factors in colorectal cancer after curative resections. DisColon Rectum 1988; 31: 33-41 [PMID: 3366023].
  • 5Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Isthere a difference in survival between right- versus left-sided coloncancers- Ann Surg Oncol 2008; 15: 2388-2394 [PMID: 18622647DOI: 10.1245/s10434-008-0015-y].
  • 6Weiss JM, Schumacher J, Allen GO, Neuman H, Lange EO,Loconte NK, Greenberg CC, Smith MA. Adjuvant chemotherapyfor stage II right-sided and left-sided colon cancer: analysis ofSEER-medicare data. Ann Surg Oncol 2014; 21: 1781-1791 [PMID:24643898 DOI: 10.1245/s10434-014-3631-8].
  • 7Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, IacopettaB. Association of tumour site and sex with survival benefitfrom adjuvant chemotherapy in colorectal cancer. Lancet2000; 355: 1745-1750 [PMID: 10832824 DOI: 10.1016/s0140-6736(00)02261-3].
  • 8Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C,Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD,Klingbiel D, Bosman FT, Delorenzi M, Tejpar S. Distal and proximalcolon cancers differ in terms of molecular, pathological, and clinicalfeatures. Ann Oncol 2014; 25: 1995-2001 [PMID: 25057166 DOI:10.1093/annonc/mdu275].
  • 9Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, WarrenRS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, AlbertsSR. Prognostic impact of deficient DNA mismatch repair in patientswith stage III colon cancer from a randomized trial of FOLFOXbasedadjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672[PMID: 24019539 DOI: 10.1200/jco.2013.48.9591].
  • 10Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, NelsonGD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, SinicropeFA. KRAS codon 12 and 13 mutations in relation to diseasefreesurvival in BRAF-wild-type stage III colon cancers from anadjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res2014; 20: 3033-3043 [PMID: 24687927 DOI: 10.1158/1078-0432.ccr-13-3140].

共引文献53

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部